Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Cancer Res ; 65(10): 4448-57, 2005 May 15.
Article in English | MEDLINE | ID: mdl-15899838

ABSTRACT

Extracts from the seeds of milk thistle, Silybum marianum, are known commonly as silibinin and silymarin and possess anticancer actions on human prostate carcinoma in vitro and in vivo. Seven distinct flavonolignan compounds and a flavonoid have been isolated from commercial silymarin extracts. Most notably, two pairs of diastereomers, silybin A and silybin B and isosilybin A and isosilybin B, are among these compounds. In contrast, silibinin is composed only of a 1:1 mixture of silybin A and silybin B. With these isomers now isolated in quantities sufficient for biological studies, each pure compound was assessed for antiproliferative activities against LNCaP, DU145, and PC3 human prostate carcinoma cell lines. Isosilybin B was the most consistently potent suppressor of cell growth relative to either the other pure constituents or the commercial extracts. Isosilybin A and isosilybin B were also the most effective suppressors of prostate-specific antigen secretion by androgen-dependent LNCaP cells. Silymarin and silibinin were shown for the first time to suppress the activity of the DNA topoisomerase IIalpha gene promoter in DU145 cells and, among the pure compounds, isosilybin B was again the most effective. These findings are significant in that isosilybin B composes no more than 5% of silymarin and is absent from silibinin. Whereas several other more abundant flavonolignans do ultimately influence the same end points at higher exposure concentrations, these findings are suggestive that extracts enriched for isosilybin B, or isosilybin B alone, might possess improved potency in prostate cancer prevention and treatment.


Subject(s)
Flavonolignans/pharmacology , Plant Extracts/pharmacology , Prostatic Neoplasms/drug therapy , Silybum marianum/chemistry , Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/genetics , Cell Cycle/drug effects , Cell Growth Processes/drug effects , Cell Line, Tumor , DNA Topoisomerases, Type II/biosynthesis , DNA Topoisomerases, Type II/genetics , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/genetics , Drug Screening Assays, Antitumor , Flavonolignans/chemistry , Flavonolignans/isolation & purification , Gene Expression/drug effects , Humans , Male , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/pathology , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Promoter Regions, Genetic/drug effects , Prostate-Specific Antigen/antagonists & inhibitors , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Topoisomerase II Inhibitors
2.
Biochemistry ; 42(6): 1430-8, 2003 Feb 18.
Article in English | MEDLINE | ID: mdl-12578355

ABSTRACT

The nuclear xenobiotic receptor PXR is activated by a wide variety of clinically used drugs and serves as a master regulator of drug metabolism and excretion gene expression in mammals. St. John's wort is used widely in Europe and the United States to treat depression. This unregulated herbal remedy leads to dangerous drug-drug interactions, however, in patients taking oral contraceptives, antivirals, or immunosuppressants. Such interactions are caused by the activation of the human PXR by hyperforin, the psychoactive agent in St. John's wort. In this study, we show that hyperforin induces the expression of numerous drug metabolism and excretion genes in primary human hepatocytes. We present the 2.1 A crystal structure of hyperforin in complex with the ligand binding domain of human PXR. Hyperforin induces conformational changes in PXR's ligand binding pocket relative to structures of human PXR elucidated previously and increases the size of the pocket by 250 A(3). We find that the mutation of individual aromatic residues within the ligand binding cavity changes PXR's response to particular ligands. Taken together, these results demonstrate that PXR employs structural flexibility to expand the chemical space it samples and that the mutation of specific residues within the ligand binding pocket of PXR tunes the receptor's response to ligands.


Subject(s)
Antidepressive Agents/chemistry , Hypericum/chemistry , Receptors, Cytoplasmic and Nuclear/chemistry , Receptors, Steroid/chemistry , Terpenes/chemistry , Animals , Antidepressive Agents/pharmacology , Binding Sites/genetics , Biopolymers/chemistry , Biopolymers/genetics , Bridged Bicyclo Compounds , Cell Line , Cells, Cultured , Chlorocebus aethiops , Computer Simulation , Crystallization , Crystallography, X-Ray , Cytochrome P-450 Enzyme System/genetics , Gene Expression Regulation/drug effects , Humans , Ligands , Models, Molecular , Mutagenesis, Site-Directed , Phloroglucinol/analogs & derivatives , Pregnane X Receptor , Protein Binding/genetics , Protein Structure, Tertiary/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Steroid/genetics , Structure-Activity Relationship , Terpenes/pharmacology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL